

1 **Multiple communication mechanisms between sensor kinases are crucial for**  
2 **virulence in *Pseudomonas aeruginosa***

3 Vanessa I. Francis<sup>1</sup>, Elaine M. Waters<sup>2</sup>, Sutharsan E. Finton-James<sup>1</sup>, Andrea Gori<sup>1</sup>,  
4 Aras Kadioglu<sup>2</sup>, Alan R. Brown<sup>1</sup>, Steven L. Porter<sup>1\*</sup>

5

6 <sup>1</sup>Biosciences, Geoffrey Pope Building, College of Life and Environmental Sciences,  
7 University of Exeter, Exeter, EX4 4QD, UK.

8 <sup>2</sup>Department of Clinical Infection, Microbiology and Immunology, Institute of Infection  
9 and Global Health, University of Liverpool, Liverpool, L69 7BE, UK.

10 \* For correspondence: Dr Steven Porter  
11 Biosciences  
12 Geoffrey Pope Building  
13 College of Life and Environmental Sciences  
14 University of Exeter  
15 Exeter  
16 EX4 4QD  
17 UK  
18 Email: [s.porter@exeter.ac.uk](mailto:s.porter@exeter.ac.uk)  
19 Telephone: +44 1392 722172

20 **ABSTRACT**

21 **Bacteria and many non-metazoan Eukaryotes respond to stresses and threats**  
22 **using two-component systems (TCSs) comprising sensor kinases (SKs) and**  
23 **response regulators (RRs). Multikinase networks, where multiple SKs work**  
24 **together, detect and integrate different signals to control important lifestyle**  
25 **decisions such as sporulation and virulence. Here, we study interactions**  
26 **between two SKs from *Pseudomonas aeruginosa*, GacS and RetS, which**  
27 **control the switch between acute and chronic virulence. We demonstrate three**  
28 **mechanisms by which RetS attenuates GacS signalling: RetS takes**  
29 **phosphoryl groups from GacS-P; RetS has transmitter phosphatase activity**  
30 **against the receiver domain of GacS-P; and RetS inhibits GacS**  
31 **autophosphorylation. These mechanisms play important roles *in vivo* and**  
32 **during infection, and exemplify an unprecedented degree of signal processing**  
33 **by SKs that may be exploited in other multikinase networks.**

## 34 INTRODUCTION

35 Canonical TCSs, comprising a single SK working with its cognate RR<sup>1,2</sup>, detect and  
36 respond to stimuli but are not well suited to making complex decisions requiring the  
37 integration of multiple signals. However, multikinase-networks, where several SKs  
38 collaborate to detect and integrate signals, can make these sophisticated decisions  
39 requiring the evaluation of multiple stimuli. Multikinase networks regulate processes  
40 as diverse as asymmetric cell division<sup>3-5</sup>, sporulation<sup>6</sup>, chemotaxis<sup>7</sup>, nitrogen  
41 metabolism<sup>8</sup>, stress responses<sup>9</sup>, virulence<sup>10,11</sup>, biofilm formation<sup>12</sup>, and differentiation  
42 into fruiting bodies<sup>13,14</sup>. Many multikinase networks feature interactions between their  
43 constituent SKs but how they affect signalling output is unclear<sup>15-17</sup>.

44 Most SKs are homodimeric proteins, containing sensory domains for detecting  
45 stimuli and controlling the activity of their catalytic core, comprising the HisKA and  
46 HATPase domains. The HATPase domain binds ATP and phosphorylates a histidine  
47 residue within the HisKA domain. For simple SKs, following autophosphorylation,  
48 phosphotransfer occurs to an aspartate in the receiver (REC) domain of the RR. In  
49 more complex SKs (~20% of bacterial and ~90% of eukaryotic examples), additional  
50 phosphorylation sites, contained within either attached REC (hybrid SKs) or attached  
51 REC and Hpt domains (unorthodox SKs)<sup>18</sup>, participate in multi-step phosphorelays,  
52 which comprise His-to-Asp and Asp-to-His phosphotransfer reactions, conveying  
53 phosphoryl groups to the RR. Phosphorylation activates the RR, mediating a  
54 response to the stimulus<sup>19</sup>. Signals are terminated by hydrolysis of the aspartyl-  
55 phosphate residue, which is an autocatalytic process, often augmented by either  
56 transmitter phosphatase activity of the SK or extrinsic phosphatases<sup>20-22</sup>. The  
57 phosphotransfer and phosphatase reactions are highly specific, ensuring fidelity of  
58 signalling<sup>23-29</sup>.

59 *Pseudomonas aeruginosa* is a leading cause of healthcare-acquired-  
60 infections<sup>30,31</sup>. It infects vulnerable patients e.g. neonates or those with cystic  
61 fibrosis, burn wounds or cancer. It causes acute and chronic infections<sup>32</sup>; acute  
62 infections (e.g. pneumonia and sepsis) feature motility and type III secretion (T3S),  
63 while, chronic infections (e.g. cystic fibrosis lung) involve biofilm production and type  
64 VI secretion (T6S)<sup>32-34</sup>. The GacS multikinase-network plays a key role in  
65 orchestrating the transition between acute and chronic infection<sup>35-38</sup>. Central to this  
66 network is the unorthodox SK, GacS, which phosphorylates the RR, GacA. GacA-P  
67 activates transcription of the regulatory RNAs, RsmY & RsmZ, which sequester the  
68 translational regulator, RsmA, thereby upregulating genes required for chronic  
69 infection and downregulating acute infection<sup>39-43</sup>.

70 Although only GacS-P phosphorylates GacA, other SKs influence GacA-P  
71 levels via GacS. LadS senses calcium<sup>44</sup>, and promotes chronic infection by  
72 phosphorylating GacS<sup>45,46</sup>. In contrast, the hybrid SK, RetS, binds and inhibits GacS  
73 via unknown mechanisms, favouring acute infection<sup>10,47-49</sup>. The ligand controlling  
74 RetS is unknown, but RetS responds to lysis of kin *P. aeruginosa* cells<sup>50</sup>. Another  
75 SK, PA1611, sequesters RetS, relieving GacS from its inhibition<sup>51,52</sup>.

76 The inhibitory interaction of RetS with GacS is considered the paradigm for  
77 negative regulation in multikinase-networks<sup>10</sup>. Previously, it was proposed that they  
78 form an inactive heterodimer incapable of autophosphorylation<sup>10</sup>. Here, we  
79 demonstrate the interactions are much more extensive, with RetS having three  
80 distinct mechanisms for downregulating GacS. All are important for RetS function  
81 and play major roles in virulence. These mechanisms represent an unprecedented  
82 level of cross-communication between SKs that can be widely utilised by other  
83 multikinase-networks.

84

85 **Results**

86 **RetS takes phosphoryl groups from GacS-P in mechanism 1.** RetS has a  
87 degenerate HATPase domain lacking the conserved G-boxes and consequently is  
88 unable to autophosphorylate. The cytoplasmic portions of GacS and RetS (denoted  
89 GacSc and RetSc) interact, and the inclusion of RetSc in GacSc  
90 autophosphorylation reactions reduces the steady-state levels of GacSc-P  
91 produced<sup>10</sup>; here, we determine the molecular mechanisms responsible. We began  
92 by testing whether RetSc could accelerate the dephosphorylation of purified GacSc-  
93 P (Fig. 1a,b); these reactions did not contain any residual ATP. We detected  
94 phosphorylation of RetSc (Fig. 1b), indicating phosphotransfer had occurred from  
95 GacSc-P to RetSc. To determine which of the three phosphorylation sites of RetS  
96 accepts the phosphoryl group from GacS-P, we prepared mutant RetSc proteins  
97 lacking these sites (wild-type RetSc, with its three native phosphorylation sites is  
98 denoted RetSc(HDD)). The mutant protein lacking the phosphorylation site in REC1  
99 (D713) was unchanged in its ability to be phosphorylated by GacSc-P  
100 (Supplementary Fig. 1). We found that the mutant proteins lacking the  
101 phosphorylation site in REC2 (D858), RetSc(HDA) and RetSc(HAA), were not  
102 phosphorylated by GacSc-P (Fig. 1c,d), indicating that D858 is phosphorylated by  
103 GacSc-P.

104 To identify which of the three phosphorylation sites of GacSc-P was the  
105 phosphodonor for this phosphotransfer reaction, we engineered a mutant GacSc  
106 protein, GacSc(HAQ), retaining only its autophosphorylation site and lacking its REC  
107 and Hpt domain phosphorylation sites. We found that when purified GacSc(HAQ)-P  
108 was coincubated with RetSc, RetSc-P was produced and the intensity of the  
109 GacSc(HAQ)-P band was decreased, meaning that phosphotransfer had occurred

110 from GacSc(HAQ)-P to RetSc (Fig. 1f). RetSc-P levels did not rise to the same  
111 extent as GacSc(HAQ)-P levels decreased during this phosphotransfer reaction  
112 because RetSc-P dephosphorylates and therefore RetSc-P levels are determined  
113 not only by the rate of phosphotransfer from GacSc(HAQ)-P but also by how quickly  
114 RetSc-P dephosphorylates. No phosphotransfer was seen from GacSc(HAQ)-P to  
115 the mutant RetSc proteins lacking D858, RetSc(HDA) and RetSc(HAA) (Fig. 1g,h).  
116 These data indicate that the autophosphorylatable His residue in the HisKA domain  
117 of GacS is a phosphodonor for D858 in REC2 of RetS. We refer to this as  
118 mechanism 1 (Fig. 1i).

119 **RetS is a transmitter phosphatase for GacS-P in mechanism 2.** Wild-type  
120 GacSc-P autodephosphorylates with a half-time of  $25 \pm 2$  mins (Fig. 1j,k). RetS  
121 mutant proteins, RetSc(HDA) (Fig. 1g) and RetSc(HAA) (Fig. 1h), lacking D858, are  
122 disabled for mechanism 1 and cannot dephosphorylate GacSc(HAQ)-P. However,  
123 they still speed up the dephosphorylation of wild-type GacSc-P (Fig. 1k); each  
124 reducing the half-time from  $25 \pm 2$  mins to  $15 \pm 1$  mins (Fig. 1k). Likewise, RetS<sub>HK</sub>,  
125 lacking both REC domains and comprising only the catalytic core (HisKA and the  
126 degenerate HATPase domain) of RetS, also reduced the GacSc-P  
127 dephosphorylation half-time (Fig. 1j,k). This suggests RetS has a second mechanism  
128 for dephosphorylating GacS-P that resides within the catalytic core of RetS, and  
129 targets either the REC or Hpt phosphorylation sites of GacS (present in wild-type  
130 GacSc-P but not in GacSc(HAQ)-P). We examined the dephosphorylation of  
131 GacSc(HDQ)-P, which lacks the phosphorylation site in the Hpt domain, and found  
132 that RetSc(HDA) and RetS<sub>HK</sub> could catalyse its dephosphorylation (Supplementary  
133 Fig. 2), indicating that the Hpt phosphorylation site is not the target and therefore the  
134 target is the REC domain phosphorylation site.

135 The majority of SKs have kinase and phosphatase activity. While RetS has a  
136 degenerate HATPase domain rendering it incapable of autophosphorylation, its  
137 HisKA domain retains the conserved H-box including the motif (HExxT) needed for  
138 transmitter phosphatase activity<sup>20,53</sup>. We therefore, hypothesised that RetS has  
139 transmitter phosphatase activity directed towards the REC domain of GacS.  
140 Consistent with this, the mutant protein, RetSc(T428A,HDA), lacking both the  
141 conserved T428 residue from the HExxT phosphatase motif, and D858 required for  
142 mechanism 1, had no ability to speed up GacSc-P dephosphorylation (Fig. 1k).  
143 Therefore, mechanism 2 is enhanced dephosphorylation of GacS-P by transmitter  
144 phosphatase activity of RetS against the REC domain of GacS (Fig. 1l).

145 **RetS inhibits the autophosphorylation of GacS in mechanism 3.** Mechanisms 1  
146 and 2, described above, dephosphorylate GacS-P. Here we tested whether RetS  
147 could affect the autophosphorylation rate of GacS; we did this using mutant versions  
148 of GacSc and RetSc where both dephosphorylation mechanisms were disabled.  
149 RetSc(HAA) cannot dephosphorylate GacSc(HAQ)-P (Fig. 1h); however, the  
150 presence of RetSc(HAA) in a GacSc(HAQ) autophosphorylation reaction, reduced  
151 the level of GacSc(HAQ)-P that accumulated (Fig. 1m). Likewise,  
152 RetSc(T428A,HDA) which is disabled for mechanisms 1 and 2 (Fig. 1k), inhibited the  
153 autophosphorylation of GacSc(HAQ) (Fig. 1m). Similar results were seen when using  
154 only the kinase catalytic cores (HisKA and HATPase domain) of GacS and RetS; the  
155 presence of RetS<sub>HK</sub> in a GacS<sub>HK</sub> autophosphorylation reaction, reduced the level of  
156 GacS<sub>HK</sub>-P that accumulated (Fig. 1n). This means there is a third mechanism of  
157 interaction between GacS and RetS where the kinase core of RetS inhibits  
158 autophosphorylation of GacS (Fig. 1o).

159 **Mechanisms 1 and 2 control biofilm formation.** To determine the relative  
160 contribution of the three mechanisms *in vivo*, we replaced the wild-type *retS* gene in  
161 the chromosome with mutant versions; the *retS*(HDA) mutant lacking mechanism 1,  
162 the *retS*(T428A) mutant lacking mechanism 2, the *retS*(T428A,HDA) mutant lacking  
163 mechanisms 1 and 2, and the  $\Delta retS$  mutant lacking all three mechanisms. We  
164 confirmed that the mutant proteins were expressed at comparable levels to wild-type  
165 RetS by western blotting (Supplementary Note 1 and Supplementary Fig. 3).

166 Deletion of *retS* enhances biofilm formation (Fig. 2)<sup>47,48,54</sup>. The *retS* point  
167 mutants (*retS*(HDA), *retS*(T428A) and *retS*(T428A,HDA)) produced significantly more  
168 biofilm than the PAO1 strain (Fig. 2a). The mutant lacking mechanism 1, *retS*(HDA),  
169 had similar biofilm levels to the  $\Delta retS$  mutant, indicating that mechanism 1 plays a  
170 major role in regulating biofilm formation. While biofilm levels were significantly  
171 higher in the *retS*(T428A) mutant than in the wild-type strain, they were not elevated  
172 to the same extent as the  $\Delta retS$  mutant, indicating that mechanism 2 plays a  
173 significant role in controlling biofilm formation although to a lesser extent than  
174 mechanism 1. To verify that the increased biofilm formation observed in the *retS*  
175 point mutants was a consequence of GacS dysregulation, we introduced these  
176 mutations into a  $\Delta gacS$  background. Like their parent  $\Delta gacS$  mutant, these double  
177 *gacS/retS* mutants produced significantly less biofilm than the PAO1 strain  
178 (Supplementary Fig. 4), consistent with the *retS* point mutations affecting signalling  
179 via GacS. These data indicate that the control of GacS signalling by mechanisms 1  
180 and 2 of RetS are important for regulating biofilm formation.

181 **Contribution of the three mechanisms to controlling RsmY&Z.** The GacS  
182 network controls the expression of two small RNAs, RsmY and RsmZ<sup>55</sup>. The  $\Delta retS$   
183 mutant has elevated levels of RsmY and RsmZ because of its increased GacS



184 activity<sup>10,55,56</sup>. We found that levels of RsmY and RsmZ were increased in all *retS*  
185 point mutant strains lacking mechanisms 1 and 2 (Fig. 2b,c), indicating that these  
186 mechanisms play major roles in controlling *rsmY* and *rsmZ* expression. The mutant  
187 lacking both mechanisms 1 and 2 (*retS*(T428A,HDA)), however, did not produce as  
188 much RsmZ as the  $\Delta retS$  mutant (Fig. 2c), suggesting that mechanism 3, alongside  
189 mechanisms 1 and 2, contributes a significant role to controlling the expression of  
190 *rsmZ*.

191 **Mechanism 1 is important for swarming motility.** Unlike the wild-type strain,  
192 PAO1, the  $\Delta retS$  mutant did not swarm (Fig. 3). We found that all mutants lacking  
193 mechanism 1, e.g. *retS*(HDA) (Fig. 3b) were unable to swarm, indicating that  
194 mechanism 1 is essential. The mutant lacking mechanism 2, *retS*(T428A), did  
195 swarm, indicating that mechanism 2 is not required (Fig. 3c).

196 **Virulence in *Galleria mellonella* requires mechanisms 1 and 2.** To assess the  
197 role of the three mechanisms in virulence, the *retS* mutants were tested in a *Galleria*  
198 *mellonella* infection model. Larvae were injected with 20-40 CFUs of PAO1 or mutant  
199 strains. The PAO1 infected larvae all died within 21 hours of infection, whereas over  
200 60 % of the larvae infected with the  $\Delta retS$  mutant survived to the end of the  
201 experiment (47 hours post-infection) (Fig. 4a). Similar to the  $\Delta retS$  mutant, the  
202 *retS*(HDA) and *retS*(T428A,HDA) mutants showed severely attenuated virulence with  
203 significantly more larvae surviving than those infected with PAO1 (Fig. 4a). The  
204 *retS*(T428A) mutant showed significantly delayed killing compared to those infected  
205 with PAO1 (Fig. 4a). We examined the phenotypes of the *retS*(HDA) $\Delta gacS$  and the  
206 *retS*(T428A) $\Delta gacS$  mutants and found that they were as virulent as the  $\Delta gacS$   
207 mutant (Fig. 4b), confirming that the reduction in virulence seen in the *retS*(HDA) and

208 *retS*(T428A) mutants were dependent on the presence of GacS and therefore a  
209 consequence of GacS dysregulation. In summary, mechanism 1 is essential for  
210 virulence in *G. mellonella* whereas loss of mechanism 2 delays killing.

211 **RetS overexpression allows mechanism 3 to support virulence.** The mutant  
212 lacking mechanisms 1 and 2, *retS*(T428A,HDA), phenocopies the  $\Delta retS$  mutant in  
213 most of the above assays, with the only significant difference being that RsmZ levels  
214 are not elevated to the same extent as the  $\Delta retS$  mutant (Fig. 2c). This indicates that  
215 mechanism 3 alone is not sufficient for RetS function, and that dephosphorylation of  
216 GacS-P, via mechanisms 1 and 2, is essential. We hypothesised that while  
217 mechanism 3 cannot compensate for the loss of mechanisms 1 and 2 at native  
218 expression levels of RetS, it may be able to compensate at higher expression levels.  
219 To test this, we overexpressed RetS(T428A,HDA), which possesses only  
220 mechanism 3, in the  $\Delta retS$  mutant. Successful complementation was seen (Fig. 4c)  
221 indicating that, at non-physiologically high expression levels, mechanism 3  
222 compensates for the loss of mechanisms 1 and 2. However, at physiological  
223 expression levels of RetS, this compensation cannot occur, and mechanisms 1 and  
224 2 are both required.

225 **Mechanisms 1 and 2 are required for virulence in mice.** We used a mouse model  
226 of acute respiratory infection to probe the role of the mechanisms in virulence. Mice  
227 were inoculated intranasally with  $2 \times 10^7$  CFUs of *P. aeruginosa*. Only 10% of mice  
228 infected with PAO1 survived beyond 28 hours of infection. All mice infected with the  
229  $\Delta retS$  mutant or the mutant lacking mechanism 1 (*retS*(HDA)) survived for the seven-  
230 day duration of the experiment, demonstrating that RetS and mechanism 1 are  
231 essential for virulence (Fig. 5). The *retS*(T428A) mutant, which lacks mechanism 2,

232 was also severely attenuated in virulence with 80% of mice surviving to the endpoint  
233 of the experiment (Fig. 5). These results indicate that mechanisms 1 and 2 are both  
234 important for acute virulence.

235 **Discussion**

236 We have shown that two SKs, RetS and GacS, which play a major role in controlling  
237 virulence in *P. aeruginosa*, interact extensively, with RetS having three distinct  
238 mechanisms for downregulating GacS signalling (Fig. 6). In mechanism 1, RetS  
239 takes phosphoryl groups from GacS-P, with phosphotransfer occurring from the  
240 autophosphorylation site of GacS to REC2 of RetS. In mechanism 2, RetS has  
241 transmitter phosphatase activity that speeds up the dephosphorylation of the REC  
242 domain of GacS-P. In mechanism 3, RetS inhibits the autophosphorylation of GacS.  
243 These three mechanisms allow RetS to have exquisite control of GacS signalling  
244 and they all play significant roles *in vivo* and during infection. In particular, we show  
245 that mechanisms 1 and 2 play vital roles during acute respiratory infection in mice.  
246 This is the first discovery of such an intricate level of interconnectedness and  
247 communication between a pair of SKs in a sensory network. This has profound  
248 implications for other sensory networks employing multiple SKs which, in light of this  
249 study, could be expected to use similar mechanisms of communication to process  
250 sensory data and integrate multiple signals. A further implication is that because of  
251 the increased number of different mechanisms by which kinase-to-kinase signalling  
252 can occur, multikinase networks may be even more widespread than previously  
253 appreciated.

254 The three mechanisms identified here represent an unprecedented level of  
255 communication between two SKs and there is great potential for them to be  
256 employed in other multikinase networks. Mechanism 1 employs intermolecular  
257 phosphotransfer to signal from the HisKA domain of one SK (GacS) to a REC  
258 domain located within another SK (RetS). Here, REC2 of RetS functions as a  
259 phosphate sink for GacS. As around 20% of SKs have a REC domain (i.e. are

260 hybrid/unorthodox), related phosphotransfer mechanisms will be found connecting  
261 many other pairs of kinases that work together<sup>12,13,18,46</sup>. Mechanism 2 uses the  
262 transmitter phosphatase activity of one SK (RetS) against the REC domain of  
263 another SK (GacS); as far as we are aware, this is the first demonstration of  
264 transmitter phosphatase activity occurring between two kinases but there is wide  
265 potential for it to be employed in other multikinase-networks because almost all SKs  
266 have transmitter phosphatase activity<sup>20</sup>. Mechanism 3 involves inhibitory interactions  
267 between the catalytic core of two kinases (RetS and GacS)<sup>10</sup>, and consistent with  
268 this mechanism being used by other networks are the findings of a systematic two-  
269 hybrid screen of the SKs from *Myxococcus xanthus*, which tested 725 possible  
270 catalytic core/catalytic core interactions and found evidence of interaction in over 100  
271 cases<sup>16</sup>.

272 Mechanism 1 depends on the phosphorylatable aspartate residue in REC2 of  
273 RetS (D858) and is essential for virulence, biofilm formation, swarming and normal  
274 expression levels of RsmY&Z. Most strikingly, the *retS*(HDA) mutant, lacking D858,  
275 was completely avirulent in mice (Fig. 5). Prior to our discovery of its key role in  
276 mechanism 1, the role of D858 had been investigated. Similar to our findings with the  
277 PAO1 strain of *P. aeruginosa*, Laskowski and Kazmierczak found that for the PA103  
278 strain, D858 is essential for RetS function<sup>56</sup>. However, in contrast, Goodman et al.,  
279 found no phenotype for the D858 mutation in the PAK strain<sup>10</sup>. This suggests that  
280 either of the two remaining mechanisms (which are independent of D858)  
281 compensate when mechanism 1 is lost in the PAK strain but not in the PAO1 and  
282 PA103 strains.

283 The three mechanisms that we have demonstrated signal via GacS to control  
284 phosphorylation levels of the output RR, GacA, which controls expression of the

285 regulatory RNAs, RsmY and RsmZ. Loss of any individual mechanism is sufficient to  
286 increase RsmY expression levels to the same extent as seen in the  $\Delta retS$  mutant  
287 (Fig. 2b), whereas although significant elevation in RsmZ levels is seen when  
288 individual mechanisms are lost, it is not to the same extent as seen with the  $\Delta retS$   
289 mutant (Fig. 2c). RsmY expression has previously been reported to be at least 2-fold  
290 higher than RsmZ expression<sup>55,58</sup>. These findings can be explained by a model  
291 where GacA-P binds more tightly to the RsmY promoter than to the RsmZ promoter.  
292 Deleting *retS*, eliminates all three of our mechanisms, thereby giving a large rise in  
293 GacA-P levels, sufficient to fully activate RsmY and RsmZ expression. The *retS* point  
294 mutations, by disabling individual mechanisms, would generate a rise in GacA-P  
295 levels but not as much as is seen in the *retS* deletion mutant. This lesser rise in  
296 GacA-P levels would be enough to fully activate the RsmY promoter (due to its  
297 higher binding affinity) but not enough to fully activate the RsmZ promoter.

298 An intriguing question is why are multiple mechanisms necessary to  
299 orchestrate this virulence switch? Presumably, each mechanism contributes uniquely  
300 to the balance of the decision-making process during infection and the complexity of  
301 this process reflects the importance of the decision to bacterial survival in the host.  
302 Differential regulation of the three mechanisms would allow precise control of GacS  
303 signalling and, given their importance for virulence, it is tempting to speculate that  
304 these elaborate mechanisms constitute a logic gate for processing and integrating  
305 the different stimuli sensed by GacS and RetS to decide the course of the infection.  
306 Although all three mechanisms allow RetS to downregulate GacS signalling, there  
307 are significant differences. For example, mechanism 3 blocks the  
308 autophosphorylation of GacS but it differs from mechanisms 1 & 2, as it is unable to  
309 dephosphorylate GacS-P. This is important because autophosphorylation is not the

310 only way of generating GacS-P, as LadS-P phosphorylates GacS<sup>46</sup>; GacS-P  
311 generated from LadS-P would be unaffected by mechanism 3 but could be targeted  
312 by mechanisms 1 and 2.

313         How might the three different mechanisms be controlled? RetS has a  
314 periplasmic ligand binding domain that has been implicated in detecting kin-cell lysis  
315 but its ligand is currently unknown<sup>50,59,60</sup>. Ligand binding could regulate any of the  
316 three mechanisms, but in other SKs there is a strong precedent for it regulating the  
317 balance between kinase activity and transmitter phosphatase activity<sup>20</sup>. RetS lacks  
318 kinase activity but, following this precedent, transmitter phosphatase activity  
319 (mechanism 2) is very likely to be under ligand control. Mechanism 1 provides  
320 considerable potential for linkage to other signalling pathways, in particular the HptB  
321 signalling pathway. HptB is a single domain Hpt protein that relays phosphoryl  
322 groups from several hybrid kinases (PA1611, ErcS' and SagS) to the output RR,  
323 HsbR, which indirectly controls motility and cyclic-di-GMP levels<sup>54,61,62</sup>. Analogous to  
324 how RetS serves as a phosphoacceptor for GacS-P in mechanism 1, RetS can also  
325 take phosphoryl groups from HptB-P<sup>61</sup>. This could provide a route for HptB signalling  
326 to downregulate mechanism 1, since when RetS is phosphorylated by HptB-P, then,  
327 until it has dephosphorylated, it will be unable to accept phosphoryl groups from  
328 GacS-P. This potential communication route would expand the number of SKs, and  
329 therefore the number of different signals, that could influence signalling by the GacS  
330 network. Aside from this HptB mediated link, PA1611 has been shown to interact  
331 directly with RetS<sup>51,52</sup>. In wild-type cells, PA1611 is expressed only at very low levels  
332 making the physiological relevance of this interaction uncertain<sup>51</sup>, however it has  
333 been found that overexpression of PA1611 using a multicopy plasmid expression  
334 vector, favours the interaction between PA1611 and RetS, and relieves GacS from

335 the inhibitory effects of RetS, suggesting that PA1611 sequesters RetS away from  
336 GacS<sup>51</sup>. The phenotypic data from PA1611 overexpression are consistent with a total  
337 loss of RetS function<sup>51,52</sup>, suggesting that the sequestration of RetS by PA1611  
338 blocks all three of the mechanisms by which RetS targets GacS.

339 In conclusion, we have discovered extensive interactions between the GacS  
340 and RetS SKs that play a critical role in controlling the switch between acute and  
341 chronic infection. We have identified three distinct biochemical mechanisms and  
342 demonstrated their important roles *in vivo* and in insect and mouse infection models.  
343 The complexity of these mechanisms reflects the importance of the finely balanced  
344 decisions that the GacS network makes during infection. As these mechanisms  
345 involve highly conserved domains or sequence motifs, they are likely to be used by  
346 many other multikinase networks for signal integration and decision-making.



347 **Methods**

348 **Bacterial strains and growth conditions.** Bacterial strains and plasmids are  
349 described in Supplementary Table 1. Unless otherwise stated bacteria were grown in  
350 LB broth at 37 °C. When used, M63 (2 g/L (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 13.6 g/L KH<sub>2</sub>PO<sub>4</sub>, and 0.5  
351 mg/L FeSO<sub>4</sub>) was supplemented with 1 mM MgSO<sub>4</sub>, 0.5 % Casamino Acids and 0.2  
352 % glucose. Antibiotics were used at the following concentrations: ampicillin 100  
353 µg/ml, kanamycin 25 µg/ml, tetracycline 50 µg/ml and gentamycin 25 µg/ml (*E. coli*)  
354 or 100 µg/ml (*P. aeruginosa*).

355 **Plasmid construction.** Genes for overexpressing wild-type cytoplasmic portions of  
356 proteins were amplified from *P. aeruginosa* PAO1 genomic DNA using primers  
357 described in Supplementary Table 2. Point mutations were introduced using overlap  
358 extension PCR. Wild-type genes and their mutant derivatives were cloned into the  
359 pQE60 expression plasmid which attaches a C-terminal 6xHis tag. The proteins were  
360 overexpressed and purified as previously described for other SKs<sup>63,64</sup>. Allelic  
361 exchange plasmids for in-frame deletion of genes in PAO1 or for introducing point  
362 mutations were constructed using primers described in Supplementary Table 2 using  
363 *P. aeruginosa* DNA as template. These constructs were cloned into pEX19Gm for  
364 allelic exchange with PAO1<sup>65,66</sup>.

365 **Strain construction.** In-frame gene deletions and allelic exchange of gene regions  
366 containing introduced point mutations were carried out by tri-parental mating using *E.*  
367 *coli* containing the mobilisation plasmid, pRK2013<sup>67</sup>. Subsequent sucrose and  
368 gentamycin susceptibility tests were done to isolate potential mutants. Deletion  
369 mutants were checked via PCR using primers outside of the initial construct used to  
370 make the deletion. PCR products were sequenced to confirm mutations. Tetra-  
371 primer PCR<sup>68</sup> was used as a preliminary screen to identify strains containing desired

372 point mutations. Potential mutants were then checked by sequencing using PCR  
373 products obtained using primers outside of the original mutation construct.

374 **Autophosphorylation assays.** Reactions were performed in TGMNKD buffer (10%  
375 (v/v) Glycerol, 150 mM NaCl, 50 mM Tris HCl, 1 mM DTT, 5 mM MgCl<sub>2</sub>, 50 mM KCl,  
376 pH 8.0) and initiated by addition of 2 mM [ $\gamma^{32}\text{P}$ ] ATP (3.7 GBq/mmol PerkinElmer).  
377 The reactions contained 5  $\mu\text{M}$  GacS derivative and 20  $\mu\text{M}$  RetS derivative (Fig. 1m-  
378 n). The final reaction volume was 100  $\mu\text{l}$ . 10  $\mu\text{l}$  aliquots were taken at the indicated  
379 timepoints and quenched in 20  $\mu\text{l}$  of 2x SDS loading dye (7.5% (w/v) SDS, 90 mM  
380 EDTA, 37.5 mM Tris pH 6.8, 37.5% Glycerol, and 3%  $\beta$ -mercaptoethanol). Samples  
381 were stored on ice and then analysed using SDS-PAGE (10% (w/v) polyacrylamide).  
382 Gels were exposed to phosphorscreens (Fuji) for 1 hour and then analysed using a  
383 Fujifilm FLA-7000 phosphorimager. The uncropped phosphorimages used to  
384 produce Fig. 1 and Supplementary Fig. 1 are shown in Supplementary Fig. 5&6.

385 **Pre-phosphorylation of GacS derivatives.** GacSc, GacSc(HAQ) and GacSc(HDQ)  
386 were purified and then incubated with 2 mM [ $\gamma^{32}\text{P}$ ] ATP (3.7 GBq/mmol PerkinElmer)  
387 for 1 hour at 20 °C. The phosphorylated proteins were then diluted in lysis buffer and  
388 purified away from unincorporated ATP using a Ni-NTA column<sup>69,70</sup>.

389 **GacS-P dephosphorylation assays.** Reaction tubes contained TGMNKD buffer  
390 and, where appropriate, RetSc or one of its mutant derivatives. The reactions were  
391 initiated by addition of phosphorylated GacS (either wild-type GacSc-P or one of its  
392 mutant derivatives). Reactions contained: 2  $\mu\text{M}$  GacSc-P and 50  $\mu\text{M}$  RetSc  
393 derivative (Fig. 1a-d and Supplementary Fig. 1a-c), 4  $\mu\text{M}$  GacSc(HAQ)-P and 20  $\mu\text{M}$   
394 RetSc derivative (Fig. 1e-h and Supplementary Fig. 1d-f), 2  $\mu\text{M}$  GacSc-P and 20  $\mu\text{M}$   
395 RetSc derivative (Fig. 1j,k), and 2  $\mu\text{M}$  GacSc(HDQ)-P and 20  $\mu\text{M}$  RetSc derivative  
396 (Supplementary Fig. 2). Reactions were performed at 20 °C. 10  $\mu\text{l}$  samples were

397 taken at the timepoints indicated and processed as described for the  
398 autophosphorylation assays. Half-times of GacSc-P dephosphorylation were  
399 calculated using Origin 4.1. Data were analysed using a One-Way ANOVA with  
400 Tukey's modification.

401 **Biofilm formation.** Biofilm formation was measured using the MBEC<sup>TM</sup> (Minimum  
402 Biofilm Eradication Concentration) Assay from Innovotech. This features a 96-well  
403 plate with a peg lid and was used according to a modified method previously  
404 described<sup>71</sup>. Overnight LB cultures were standardised in LB broth to an OD<sub>600nm</sub>=1.0,  
405 which were then diluted 1:100 in M63. In each well, 150 µl of diluted culture or  
406 uninoculated broth was dispensed before the sterile peg lid was sealed on the plate.  
407 Each strain had 5 technical repeats per plate. The plates were incubated for 10 hrs  
408 at 37 °C with shaking at 125 rpm. Peg lids were removed and washed in PBS before  
409 being dried at 65 °C. Dried lids were stained with 0.1% (w/v) crystal violet. The pegs  
410 were washed 3 times in PBS, 5 minutes per wash, before bound crystal violet was  
411 solubilised in 95% ethanol. These plates were read at OD<sub>570nm</sub>. Three biological  
412 repeats were performed.

413 **RNA extraction, cDNA and qPCR.** Overnight cultures were subcultured into LB  
414 broth with a starting OD<sub>600nm</sub> of 0.03 and incubated for 6 hrs at 37 °C with shaking.  
415 Cells were harvested and processed following the supplier's protocol through the  
416 RiboPure Bacteria Kit (Ambion), which includes a DNA removal step, which was  
417 repeated twice. Purified RNA was checked by PCR for DNA contamination before  
418 cDNA was made using SuperScript III reverse Transcriptase (Life Technologies)  
419 following the supplier's protocol. Quantitative real time PCR (qRT-PCR) was carried  
420 out on a Stratagene Mx3005P machine using Brilliant III Ultra-Fast SYBR Green  
421 qPCR kit (Agilent Technologies) following the manufacturer's protocol. The

422 oligonucleotides used are detailed in Supplementary Table 2. The housekeeping  
423 gene *rpoC* was used as an internal control. Fold changes in expression were calculated  
424 using the  $2^{-\Delta\Delta C_T}$  method<sup>72</sup>. Data were analysed using a one-way ANOVA with  
425 contrasts.

426 **Swarming motility assay.** Large swarming plates (140 mm) contained 0.5% (w/v)  
427 agar (LAB Agar No2 Bacteriological) and 8 g/L nutrient broth (Oxoid) supplemented  
428 with 0.5% (w/v) glucose. Plates were inoculated with 0.5  $\mu$ l overnight culture,  
429 incubated at 20 °C for 2 hrs prior to incubation at 30 °C for 16 hrs. Plates were then  
430 incubated at 20 °C for a further 8 hours before imaging.

431 ***Galleria mellonella* infection model.** *Galleria* larvae killing was performed based on  
432 a previously described assay<sup>73</sup>. *Galleria* larvae were obtained from UK Waxworms  
433 Ltd (Sheffield, UK). *P. aeruginosa* strains were grown overnight in M63 before being  
434 centrifuged, washed and resuspended in PBS to an  $OD_{590}=1 \pm 0.05$ . This was diluted  
435  $5 \times 10^5$  fold in PBS. Using a gastight repeat dispenser Hamilton syringe, 2 X 5  $\mu$ l of  
436 the diluted bacterial suspension (20–40 CFUs) were injected into the hindmost proleg  
437 of the larvae. Larvae were incubated at 37 °C and their survival was monitored after  
438 15 hours of incubation for up to 47 hours. Data were analysed using Kaplan-Meier  
439 survival curves. Statistical significance was assessed using the Mantel-Cox Log  
440 Rank test, applying Bonferroni's correction for multiple comparisons.

441 **Mouse respiratory infection model.** The mouse infection model was done as  
442 previously described<sup>74</sup>. 7-9 week old female Balb/c mice (Harlan) were anesthetized  
443 with  $O_2$  and isoflurane and infected intranasally with a challenge dose of  $2 \times 10^7$   
444 CFUs. Two independent experiments were performed, each with five mice per strain.  
445 Power calculations were used to estimate the number of mice needed to detect a 10  
446 % change in the mean survival time. Mice were randomly assigned to each of the

447 treatment groups. No blinding was used. Survival was followed over 7 days and  
448 scored as previously described<sup>74</sup>. Mouse experiments were approved by the United  
449 Kingdom Home Office (Home Office Project License Number 40/3602) and the  
450 University of Liverpool Animal Welfare and Ethics Committee.

451 **Western Blot.** Overnight LB cultures were standardised in LB broth to an  
452 OD<sub>600nm</sub>=1.0, which were then diluted 1:100 in M63. Cells were incubated for 10 hrs  
453 at 37 °C with shaking at 125 rpm. 1 ml of cells was centrifuged at 13,000 rpm. Cell  
454 pellets were resuspended in 100 µl of BugBuster (Merck) and incubated at 20 °C for  
455 20 minutes to lyse cells. 25 µl NuPAGE® LDS sample buffer (4X) (Invitrogen) was  
456 added and samples were boiled for 5 minutes at 100 °C. Whole cell lysates were  
457 separated using Bis-Tris NuPAGE® Novex® 4 to 12% SDS-PAGE gels (Invitrogen).  
458 Proteins were electrically transferred to a nitrocellulose membrane (Fisher) and  
459 blocked overnight at 4 °C using 3% (w/v) skimmed milk (Sigma) in TPBS (PBS  
460 supplemented with 1% (v/v) Tween-20). The membrane was incubated at 20 °C for  
461 30 mins before being incubated for 90 minutes with 3% (w/v) skimmed milk in TPBS  
462 with the primary antibody (rabbit) diluted 1:1000. The primary rabbit antibody was  
463 raised against the purified cytoplasmic portion of RetS (Eurogentec). The membrane  
464 was washed three times for 5 minutes in TPBS. It was then incubated for 90 minutes  
465 with a secondary antibody (goat anti-rabbit) with an infrared dye (IRDye® 800W  
466 secondary antibodies from *Li-Cor*) diluted 1:25000 in TPBS with 3% (w/v) skimmed  
467 milk. The membrane was washed three times for 5 minutes with TPBS and imaged  
468 on the *Li-Cor* Odyssey.

#### 469 **Data availability**

470 The authors declare that the data supporting the findings of this study are available  
471 within the paper and its supplementary information files.

## References

472

473

- 474 1. Stock, A.M., Robinson, V.L. & Goudreau, P.N. Two-component signal transduction. *Annu. Rev. Biochem.* **69**, 183-215 (2000).
- 475 2. Skerker, J.M., Prasol, M.S., Perchuk, B.S., Biondi, E.G. & Laub, M.T. Two-component signal  
476 transduction pathways regulating growth and cell cycle progression in a bacterium: a  
477 system-level analysis. *PLoS Biol.* **3**, e334 (2005).
- 478 3. Kirkpatrick, C.L. & Viollier, P.H. Decoding *Caulobacter* development. *FEMS Microbiol. Rev.* **36**,  
479 193-205 (2012).
- 480 4. Tsokos, C.G., Perchuk, B.S. & Laub, M.T. A dynamic complex of signaling proteins uses polar  
481 localization to regulate cell-fate asymmetry in *Caulobacter crescentus*. *Dev. Cell* **20**, 329-341  
482 (2011).
- 483 5. Childers, W.S. et al. Cell fate regulation governed by a repurposed bacterial histidine kinase.  
484 *PLoS Biol.* **12**, e1001979 (2014).
- 485 6. Jiang, M., Shao, W., Perego, M. & Hoch, J.A. Multiple histidine kinases regulate entry into  
486 stationary phase and sporulation in *Bacillus subtilis*. *Mol. Microbiol.* **38**, 535-542 (2000).
- 487 7. Porter, S.L., Wadhams, G.H. & Armitage, J.P. Signal processing in complex chemotaxis  
488 pathways. *Nat. Rev. Microbiol.* **9**, 153-165 (2011).
- 489 8. Drepper, T. et al. Cross-talk towards the response regulator NtrC controlling nitrogen  
490 metabolism in *Rhodobacter capsulatus*. *FEMS Microbiol. Lett.* **258**, 250-256 (2006).
- 491 9. Mike, L.A. et al. Two-component system cross-regulation integrates *Bacillus anthracis*  
492 response to heme and cell envelope stress. *PLoS Pathog.* **10**, e1004044 (2014).
- 493 10. Goodman, A.L. et al. Direct interaction between sensor kinase proteins mediates acute and  
494 chronic disease phenotypes in a bacterial pathogen. *Genes Dev.* **23**, 249-259 (2009).
- 495 11. Ng, W.L. & Bassler, B.L. Bacterial quorum-sensing network architectures. *Annu. Rev. Genet.*  
496 **43**, 197-222 (2009).
- 497 12. Mikkelsen, H., Hui, K., Barraud, N. & Filloux, A. The pathogenicity island encoded  
498 PvrSR/RcsCB regulatory network controls biofilm formation and dispersal in *Pseudomonas*  
499 *aeruginosa* PA14. *Mol. Microbiol.* **89**, 450-463 (2013).
- 500 13. Schramm, A., Lee, B. & Higgs, P.I. Intra- and inter-protein phosphorylation between two  
501 hybrid histidine kinases controls *Myxococcus xanthus* developmental progression. *J. Biol.*  
502 *Chem.* **287**, 25060-25072 (2012).
- 503 14. Higgs, P.I., Cho, K.Y., Whitworth, D.E., Evans, L.S. & Zusman, D.R. Four unusual two-  
504 component signal transduction homologs, RedC to RedF, are necessary for timely  
505 development in *Myxococcus xanthus*. *J. Bacteriol.* **187**, 8191-8195 (2005).
- 506 15. Willett, J.W. & Crosson, S. Atypical modes of bacterial histidine kinase signaling. *Mol.*  
507 *Microbiol.* **103**, 197-202 (2017).
- 508 16. Whitworth, D.E., Millard, A., Hodgson, D.A. & Hawkins, P.F. Protein-protein interactions  
509 between two-component system transmitter and receiver domains of *Myxococcus xanthus*.  
510 *Proteomics* **8**, 1839-1842 (2008).
- 511 17. Francis, V.I., Stevenson, E.C. & Porter, S.L. Two-component systems required for virulence in  
512 *Pseudomonas aeruginosa*. *FEMS Microbiol. Lett.* **364**, fnx104 (2017).
- 513 18. Wuichet, K., Cantwell, B.J. & Zhulin, I.B. Evolution and phyletic distribution of two-  
514 component signal transduction systems. *Curr. Opin. Microbiol.* **13**, 219-225 (2010).
- 515 19. Galperin, M.Y. Structural classification of bacterial response regulators: diversity of output  
516 domains and domain combinations. *J. Bacteriol.* **188**, 4169-4182 (2006).
- 517 20. Huynh, T.N. & Stewart, V. Negative control in two-component signal transduction by  
518 transmitter phosphatase activity. *Mol. Microbiol.* **82**, 275-286 (2011).
- 519 21. Silversmith, R.E. Auxiliary phosphatases in two-component signal transduction. *Curr. Opin.*  
520 *Microbiol.* **13**, 177-183 (2010).
- 521

- 522 22. Dutta, R., Yoshida, T. & Inouye, M. The critical role of the conserved Thr247 residue in the  
523 functioning of the osmosensor EnvZ, a histidine kinase/phosphatase, in *Escherichia coli*. *J.*  
524 *Biol. Chem.* **275**, 38645-38653 (2000).
- 525 23. Skerker, J.M. et al. Rewiring the specificity of two-component signal transduction systems.  
526 *Cell* **133**, 1043-1054 (2008).
- 527 24. Podgornaia, A.I. & Laub, M.T. Determinants of specificity in two-component signal  
528 transduction. *Curr. Opin. Microbiol.* **16**, 156-162 (2013).
- 529 25. Willett, J.W. et al. Specificity residues determine binding affinity for two-component signal  
530 transduction systems. *mBio* **4**, e00420-13 (2013).
- 531 26. Kenney, L.J. How important is the phosphatase activity of sensor kinases? *Curr. Opin.*  
532 *Microbiol.* **13**, 168-176 (2010).
- 533 27. Siryaporn, A. & Goulian, M. Characterizing cross-talk *in vivo*: avoiding pitfalls and  
534 overinterpretation. *Methods Enzymol.* **471**, 1-16 (2010).
- 535 28. Laub, M.T. & Goulian, M. Specificity in two-component signal transduction pathways. *Annu.*  
536 *Rev. Genet.* **41**, 121-145 (2007).
- 537 29. Capra, E.J., Perchuk, B.S., Skerker, J.M. & Laub, M.T. Adaptive mutations that prevent  
538 crosstalk enable the expansion of paralogous signaling protein families. *Cell* **150**, 222-232  
539 (2012).
- 540 30. Brewer, S.C., Wunderink, R.G., Jones, C.B. & Leeper, K.V., Jr. Ventilator-associated  
541 pneumonia due to *Pseudomonas aeruginosa*. *Chest* **109**, 1019-1029 (1996).
- 542 31. Pendleton, J.N., Gorman, S.P. & Gilmore, B.F. Clinical relevance of the ESKAPE pathogens.  
543 *Expert Rev. Anti Infect. Ther.* **11**, 297-308 (2013).
- 544 32. Furukawa, S., Kuchma, S.L. & O'Toole, G.A. Keeping their options open: acute versus  
545 persistent infections. *J. Bacteriol.* **188**, 1211-1217 (2006).
- 546 33. Costerton, J.W., Stewart, P.S. & Greenberg, E.P. Bacterial biofilms: a common cause of  
547 persistent infections. *Science* **284**, 1318-1322 (1999).
- 548 34. Valentini, M., Gonzalez, D., Mavridou, D.A.I. & Filloux, A. Lifestyle transitions and adaptive  
549 pathogenesis of *Pseudomonas aeruginosa*. *Curr. Opin. Microbiol.* **41**, 15-20 (2018).
- 550 35. Lapouge, K., Schubert, M., Allain, F.H. & Haas, D. Gac/Rsm signal transduction pathway of  $\gamma$ -  
551 proteobacteria: from RNA recognition to regulation of social behaviour. *Mol. Microbiol.* **67**,  
552 241-253 (2008).
- 553 36. Coggan, K.A. & Wolfgang, M.C. Global regulatory pathways and cross-talk control  
554 *Pseudomonas aeruginosa* environmental lifestyle and virulence phenotype. *Curr. Issues Mol.*  
555 *Biol.* **14**, 47-69 (2012).
- 556 37. Raghavan, V. & Groisman, E.A. Orphan and hybrid two-component system proteins in health  
557 and disease. *Curr. Opin. Microbiol.* **13**, 226-231 (2010).
- 558 38. Balasubramanian, D., Schneper, L., Kumari, H. & Mathee, K. A dynamic and intricate  
559 regulatory network determines *Pseudomonas aeruginosa* virulence. *Nucleic Acids Res.* **41**, 1-  
560 20 (2013).
- 561 39. Pessi, G. et al. The global posttranscriptional regulator RsmA modulates production of  
562 virulence determinants and N-Acylhomoserine lactones in *Pseudomonas aeruginosa*. *J.*  
563 *Bacteriol.* **183**, 6676-6683 (2001).
- 564 40. Heurlier, K. et al. Positive control of swarming, rhamnolipid synthesis, and lipase production  
565 by the posttranscriptional RsmA/RsmZ system in *Pseudomonas aeruginosa* PAO1. *J.*  
566 *Bacteriol.* **186**, 2936-2945 (2004).
- 567 41. Burrowes, E., Baysse, C., Adams, C. & O'Gara, F. Influence of the regulatory protein RsmA on  
568 cellular functions in *Pseudomonas aeruginosa* PAO1, as revealed by transcriptome analysis.  
569 *Microbiology* **152**, 405-418 (2006).
- 570 42. Gooderham, W.J. & Hancock, R.E.W. Regulation of virulence and antibiotic resistance by  
571 two-component regulatory systems in *Pseudomonas aeruginosa*. *FEMS Microbiol. Rev.* **33**,  
572 279-294 (2009).

- 573 43. Allsopp, L.P. et al. RsmA and AmrZ orchestrate the assembly of all three type VI secretion  
574 systems in *Pseudomonas aeruginosa*. *Proc. Natl. Acad. Sci. USA* **114**, 7707-7712 (2017).
- 575 44. Broder, U.N., Jaeger, T. & Jenal, U. LadS is a calcium-responsive kinase that induces acute-to-  
576 chronic virulence switch in *Pseudomonas aeruginosa*. *Nat. Microbiol.* **2**, 16184 (2016).
- 577 45. Ventre, I. et al. Multiple sensors control reciprocal expression of *Pseudomonas aeruginosa*  
578 regulatory RNA and virulence genes. *Proc. Natl. Acad. Sci. USA* **103**, 171-176 (2006).
- 579 46. Chambonnier, G. et al. The hybrid histidine kinase LadS Forms a multicomponent signal  
580 transduction system with the GacS/GacA two-component system in *Pseudomonas*  
581 *aeruginosa*. *PLoS Genet.* **12**, e1006032 (2016).
- 582 47. Goodman, A.L. et al. A signaling network reciprocally regulates genes associated with acute  
583 infection and chronic persistence in *Pseudomonas aeruginosa*. *Dev. Cell* **7**, 745-754 (2004).
- 584 48. Laskowski, M.A., Osborn, E. & Kazmierczak, B.I. A novel sensor kinase–response regulator  
585 hybrid regulates type III secretion and is required for virulence in *Pseudomonas aeruginosa*.  
586 *Mol. Microbiol.* **54**, 1090-1103 (2004).
- 587 49. Workentine, M.L., Chang, L., Ceri, H. & Turner, R.J. The GacS-GacA two-component  
588 regulatory system of *Pseudomonas fluorescens*: a bacterial two-hybrid analysis. *FEMS*  
589 *Microbiol. Lett.* **292**, 50-56 (2009).
- 590 50. LeRoux, M. et al. Kin cell lysis is a danger signal that activates antibacterial pathways of  
591 *Pseudomonas aeruginosa*. *eLife* **4**, e05701 (2015).
- 592 51. Kong, W. et al. Hybrid sensor kinase PA1611 in *Pseudomonas aeruginosa* regulates  
593 transitions between acute and chronic infection through direct interaction with RetS. *Mol.*  
594 *Microbiol.* **88**, 784-797 (2013).
- 595 52. Bhagirath, A.Y. et al. Characterization of the direct interaction between hybrid sensor  
596 kinases PA1611 and RetS that controls biofilm formation and the type III secretion system in  
597 *Pseudomonas aeruginosa*. *ACS Infect. Dis.* **3**, 162-175 (2017).
- 598 53. Willett, J.W. & Kirby, J.R. Genetic and biochemical dissection of a HisKA domain identifies  
599 residues required exclusively for kinase and phosphatase activities. *PLoS Genet.* **8**, e1003084  
600 (2012).
- 601 54. Bordi, C. et al. Regulatory RNAs and the HptB/RetS signalling pathways fine-tune  
602 *Pseudomonas aeruginosa* pathogenesis. *Mol. Microbiol.* **76**, 1427-1443 (2010).
- 603 55. Brencic, A. et al. The GacS/GacA signal transduction system of *Pseudomonas aeruginosa* acts  
604 exclusively through its control over the transcription of the RsmY and RsmZ regulatory small  
605 RNAs. *Mol. Microbiol.* **73**, 434-445 (2009).
- 606 56. Laskowski, M.A. & Kazmierczak, B.I. Mutational analysis of RetS, an unusual sensor kinase-  
607 response regulator hybrid required for *Pseudomonas aeruginosa* virulence. *Infect. Immun.*  
608 **74**, 4462-4473 (2006).
- 609 57. Grocock, R.J. & Sharp, P.M. Synonymous codon usage in *Pseudomonas aeruginosa* PA01.  
610 *Gene* **289**, 131-139 (2002).
- 611 58. Kay, E. et al. Two GacA-dependent small RNAs modulate the quorum-sensing response in  
612 *Pseudomonas aeruginosa*. *J. Bacteriol.* **188**, 6026-6033 (2006).
- 613 59. Jing, X., Jaw, J., Robinson, H.H. & Schubot, F.D. Crystal structure and oligomeric state of the  
614 RetS signaling kinase sensory domain. *Proteins* **78**, 1631-1640 (2010).
- 615 60. Vincent, F. et al. Distinct oligomeric forms of the *Pseudomonas aeruginosa* RetS sensor  
616 domain modulate accessibility to the ligand binding site. *Environ. Microbiol.* **12**, 1775-1786  
617 (2010).
- 618 61. Hsu, J.L., Chen, H.C., Peng, H.L. & Chang, H.Y. Characterization of the histidine-containing  
619 phosphotransfer protein B-mediated multistep phosphorelay system in *Pseudomonas*  
620 *aeruginosa* PAO1. *J. Biol. Chem.* **283**, 9933-9944 (2008).
- 621 62. Valentini, M., Laventie, B.-J., Moscoso, J., Jenal, U. & Filloux, A. The diguanylate cyclase HsbD  
622 intersects with the HptB regulatory cascade to control *Pseudomonas aeruginosa* biofilm and  
623 motility. *PLoS Genet.* **12**, e1006354 (2016).



624 63. Porter, S.L., Wadhams, G.H. & Armitage, J.P. *In vivo* and *in vitro* analysis of the *Rhodobacter*  
625 *sphaeroides* chemotaxis signaling complexes. *Methods Enzymol.* **423**, 392-413 (2007).  
626 64. Scott, K.A. et al. Specificity of localization and phosphotransfer in the CheA proteins of  
627 *Rhodobacter sphaeroides*. *Mol. Microbiol.* **76**, 318-330 (2010).  
628 65. Hoang, T.T., Karkhoff-Schweizer, R.R., Kutchma, A.J. & Schweizer, H.P. A broad-host-range  
629 Flp-FRT recombination system for site-specific excision of chromosomally-located DNA  
630 sequences: application for isolation of unmarked *Pseudomonas aeruginosa* mutants. *Gene*  
631 **212**, 77-86 (1998).  
632 66. Guvener, Z.T. & Harwood, C.S. Subcellular location characteristics of the *Pseudomonas*  
633 *aeruginosa* GGDEF protein, WspR, indicate that it produces cyclic-di-GMP in response to  
634 growth on surfaces. *Mol. Microbiol.* **66**, 1459-1473 (2007).  
635 67. Figurski, D.H. & Helinski, D.R. Replication of an origin-containing derivative of plasmid RK2  
636 dependent on a plasmid function provided in trans. *Proc. Natl. Acad. Sci. USA* **76**, 1648-1652  
637 (1979).  
638 68. Ye, S., Dhillon, S., Ke, X., Collins, A.R. & Day, I.N.M. An efficient procedure for genotyping  
639 single nucleotide polymorphisms. *Nucleic Acids Res.* **29**, e88-e88 (2001).  
640 69. Amin, M. et al. Phosphate sink containing two-component signaling systems as tunable  
641 threshold devices. *PLoS Comput. Biol.* **10**, e1003890 (2014).  
642 70. Amin, M., Porter, S.L. & Soyer, O.S. Split histidine kinases enable ultrasensitivity and  
643 bistability in two-component signaling networks. *PLoS Comput. Biol.* **9**, e1002949 (2013).  
644 71. O'Toole, G.A. & Kolter, R. Flagellar and twitching motility are necessary for *Pseudomonas*  
645 *aeruginosa* biofilm development. *Mol. Microbiol.* **30**, 295-304 (1998).  
646 72. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time  
647 quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* **25**, 402-408 (2001).  
648 73. Seed, K.D. & Dennis, J.J. Development of *Galleria mellonella* as an alternative infection  
649 model for the *Burkholderia cepacia* Complex. *Infect. Immun.* **76**, 1267-1275 (2008).  
650 74. Carter, M.E.K. et al. A subtype of a *Pseudomonas aeruginosa* cystic fibrosis epidemic strain  
651 exhibits enhanced virulence in a murine model of acute respiratory infection. *J. Infect. Dis.*  
652 **202**, 935-942 (2010).

653

654

655

656 **Acknowledgements**

657 This work was supported by the Medical Research Council (MRC) [grant number  
658 MR/M020045/1], the Leverhulme Trust [grant number RPG-2014-228], the  
659 RoseTrees Trust [grant number M328] and a NERC PhD studentship [grant number  
660 1076449]. We are grateful to Lily Byham, Charlotte Unwin and Adam Wise for their  
661 assistance. We would like to thank Alain Filloux for useful discussions.

662 **Author contributions**

663 V.I.F., S.E.F-J, A.G., E.W and S.L.P. conducted the experiments; V.I.F., E.W., A.K.,  
664 A.R.B. and S.L.P. designed the experiments and wrote the paper.

665 **Competing interests**

666 The authors declare no competing interests.

667

668 **Figure legends**

669 **Figure 1 | RetS downregulates GacS signalling via three distinct mechanisms.**

670 **a-i**, Mechanism 1 – RetS takes phosphoryl groups from GacS-P. Phosphorimages of  
671 SDS-PAGE gels showing phosphotransfer from (**a-d**) GacSc-P to (**a**) buffer control,  
672 (**b**) RetSc, (**c**) RetSc(HDA) and (**d**) RetSc(HAA), and from (**e-h**) GacSc(HAQ)-P to  
673 (**e**) buffer control, (**f**) RetSc, (**g**) RetSc(HDA) and (**h**) RetSc(HAA). Experiments were  
674 repeated 5 times and a representative image shown. **i**, Cartoon depicting  
675 mechanism 1, where phosphotransfer occurs from the His residue in the HisKA  
676 domain of GacS to D858 in REC2 of RetS.

677 **j-l**, Mechanism 2 - RetS has transmitter phosphatase activity against GacS-P. **j**,  
678 Phosphorimages of SDS-PAGE gels measuring the dephosphorylation of GacSc-P  
679 alone (*top*) and with RetS<sub>HK</sub> (*bottom*). **k**, GacS-P dephosphorylation half-times in the  
680 presence of various RetS mutant proteins. Error bars show SEM from 8 replicates. \*  
681 significantly faster than GacSc-P autodephosphorylation ( $P < 0.05$ , one-way  
682 ANOVA). **l**, Cartoon depicting mechanism 2, where RetS uses transmitter  
683 phosphatase activity against the REC domain of GacS-P.

684 **m-o**, Mechanism 3 - RetS inhibits the GacS autophosphorylation reaction.  
685 Phosphorimages of SDS-PAGE gels comparing the autophosphorylation of: (**m**)  
686 GacSc(HAQ) on its own (*top*), with RetSc(HAA) (*middle*), and with  
687 RetSc(T428A,HDA) (*bottom*). (**n**) GacS<sub>HK</sub> on its own (*top*) and with RetS<sub>HK</sub> (*bottom*).  
688 Experiments were repeated 8 times and a representative image shown. **o**, Cartoon  
689 depicting mechanism 3, where the catalytic core of RetS blocks the  
690 autophosphorylation of GacS.

691 **Figure 2 | Mechanisms 1 and 2 control biofilm formation and the expression**  
692 **levels of RsmY, while all three mechanisms contribute to controlling RsmZ**

693 **levels. a**, Quantification of biofilm formation on peg-lidded 96-well plate by crystal  
694 violet staining. Plates inoculated with the mutant strains were incubated for 10 hrs  
695 with shaking at 37 °C. Error bars show SEM (three biological repeats each  
696 containing five technical repeats). \* indicates significantly different comparisons ( $P <$   
697 0.05, one-way ANOVA). See also Supplementary Fig. 4 for these mutations in a  
698  $\Delta gacS$  background. **b,c**, Relative expression level of RsmY (**b**) and RsmZ (**c**) in the  
699 mutant strains relative to the wild-type PAO1 strain. RNA levels were measured  
700 using qRT-PCR. Error bars show SEM (three biological repeats, with 3 technical  
701 repeats per biological repeat). \* indicates significantly different comparisons ( $P <$   
702 0.05, one-way ANOVA). The mechanisms disabled in each mutant strain are  
703 indicated.

704 **Figure 3 | Mechanism 1 is required for swarming motility. a-d**, Representative  
705 images of the swarming of the wild-type PAO1 strain and its mutant derivatives.  
706 Experiments were repeated three times. The mechanisms disabled in each mutant  
707 strain are indicated in circles.

708 **Figure 4 | Mechanisms 1 and 2 are important for virulence in *Galleria***  
709 ***mellonella*.**

710 **a**, Survival of *G. mellonella* larvae infected with the *retS* mutant strains. \* indicates  
711 strains showing significantly attenuated virulence compared to PAO1 ( $P < 0.01$ ,  
712 Mantel-Cox Log Rank with Bonferroni's correction for multiple comparisons). **b**, The  
713 *retS* point mutations have no phenotype in a  $\Delta gacS$  background. \* indicates strains  
714 showing significantly attenuated virulence compared to PAO1 ( $P < 0.01$ , Mantel-Cox  
715 Log Rank with Bonferroni's correction for multiple comparisons). **c**, Complementation  
716 of the  $\Delta retS$  mutant by overexpressing RetS(T428A,HDA). \* significantly more  
717 virulent than the  $\Delta retS$ -pJN105 strain ( $P < 0.01$ , Mantel-Cox Log Rank with

718 Bonferroni's correction for multiple comparisons). **a-c**, The mechanisms absent from  
719 each strain are indicated in grey circles (except in the  $\Delta gacS$  background strains that  
720 lack the target of these mechanisms). Three independent experiments were  
721 conducted each with 10 larvae per strain (30 larvae in total per mutant). The  
722 inoculum was 20-40 CFUs per larvae.

723 **Figure 5 | Mechanisms 1 and 2 are important for virulence in mice.** Survival of  
724 mice infected intranasally with the *retS* mutant strains. Mice infected with the wild-  
725 type PAO1 strain developed an acute respiratory infection. Two independent  
726 experiments were performed, each with 5 mice per mutant strain (10 mice per  
727 mutant strain). The inoculum was  $2 \times 10^7$  CFUs per mouse. \* indicates strains  
728 showing significantly attenuated virulence compared to PAO1 ( $P < 0.01$ , Mantel-Cox  
729 Log Rank with Bonferroni's correction for multiple comparisons). The mechanisms  
730 absent from each strain are indicated in grey circles.

731 **Figure 6 | The three mechanisms used by RetS to inhibit GacS signalling.**  
732 Mechanism **1** – D858 in REC2 of RetS takes the phosphoryl group from the  
733 autophosphorylatable His residue in the HisKA domain of GacS. Mechanism **2** –  
734 RetS uses its transmitter phosphatase activity to accelerate the dephosphorylation of  
735 the REC domain of GacS-P. Mechanism **3** – The catalytic core of RetS inhibits the  
736 GacS autophosphorylation reaction.

737













